Virtus LifeSci Biotech Products ETFBBP
BBP
0
Funds holding %
of 6,812 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more capital invested
Capital invested by funds: $4M [Q2] → $4.81M (+$816K) [Q3]
8% more funds holding
Funds holding: 12 [Q2] → 13 (+1) [Q3]
2.45% more ownership
Funds ownership: 19.42% [Q2] → 21.88% (+2.45%) [Q3]
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for BBP.
Financial journalist opinion
Positive
Zacks Investment Research
6 months ago
4 Best-Performing Sector ETFs of June
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
Positive
Zacks Investment Research
11 months ago
Biotech ETFs Stage Solid Comeback at the Start of 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
Charts implemented using Lightweight Charts™